Reading view

New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

© Mike Blake/Reuters

Eli Lilly company offices in San Diego. The company reported results of retatrutide, its next-generation weight-loss drug.
  •  

Why Some Doctors Say There Are Cancers That Shouldn’t Be Treated

Statistics show a clear spike in eight cancers in younger people, but that has brought a debate over whether many cases ever needed to be found.

© Michael Macor/San Francisco Chronicle, via Getty Images

An image of a patient’s prostate. Patients in the early stages of prostate cancer and other types of cancer might safely wait to see if the disease progresses.
  •  

After Trump’s MRI Claim, His Doctor’s Memo Offers Little Clarity

While the president said he had an M.R.I. exam, a physician’s memo released by the White House was less specific.

© Tierney L. Cross/The New York Times

The statement, by Dr. Sean P. Barbabella, said the tests on President Trump’s cardiovascular system and abdominal region showed the president “remains in excellent overall health.”
  •  

GLP-1 Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials

The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases.

© Hollie Adams/Reuters

A trial of semaglutide, the miracle drug branded as Ozempic and Wegovy for diabetes and weight loss, failed to find any effect of the drug on cognition and functioning in people with mild cognitive impairment or dementia.
  •  

Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future

The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease risk.

© Andrew Kelly/Reuters

Merck, which first introduced statins to the world nearly 40 years ago, announced that its new pill helped reduce heart attack and stroke rates in high risk patients by 20 percent in a year.
  •  

The Editor Got a Letter From ‘Dr. B.S.’ So Did a Lot of Other Editors.

The rise of artificial intelligence has produced serial writers to science and medical journals, most likely using chatbots to boost the number of citations they’ve published.

© Eva Manez/Reuters

A research scientist who published a paper in a scientific journal about controlling mosquito-borne malaria infections was asked to rebut a letter to the editor sent by a scientist who had suddenly become improbably prolific starting in 2025.
  •  

The Editor Got a Letter From ‘Dr. B.S.’ So Did a Lot of Other Editors.

The rise of artificial intelligence has produced serial writers to science and medical journals, most likely using chatbots to boost the number of citations they’ve published.

© Eva Manez/Reuters

A research scientist who published a paper in a scientific journal about controlling mosquito-borne malaria infections was asked to rebut a letter to the editor sent by a scientist who had suddenly become improbably prolific starting in 2025.
  •